Pharmala Biotech Holdings (FRA:ZO8) 14-Day RSI: N/A (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZO8 Pharmala Biotech Holdings Inc FRA:ZO8
38 GF Score
Price €0.14
GF Value €0.15
! 2 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-09-04), Pharmala Biotech Holdings's 14-Day RSI is N/A.

The industry rank for Pharmala Biotech Holdings's 14-Day RSI or its related term are showing as below:

FRA:ZO8's 14-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 48.27
* Ranked among companies with meaningful 14-Day RSI only.

Pharmala Biotech Holdings  (FRA:ZO8) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Pharmala Biotech Holdings 14-Day RSI Related Terms


FRA:ZO8 vs : 14-Day RSI Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's 14-Day RSI falls into.


FRA:ZO8
38GF Score
Pharmala Biotech Holdings Inc FRA:ZO8
14-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings  (FRA:ZO8) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Pharmala Biotech Holdings (FRA:ZO8) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of €0.14 is trading 7.7% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:ZO8:

  • 14-Day RSI: N/A
  • GF Value™: €0.15 vs. price of €0.14 (7.7% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the FRA:ZO8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmala Biotech Holdings Business Description

Comparable Companies
Other Exchanges MDXXF:USAMDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score

Get the complete analysis for FRA:ZO8

14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.15
GF Value